Wegovy Maker Novo Nordisk Sues Nine Spas, Clinics and Pharmacies Over Copycat Drugs

May 31, 2024
Weight loss drugs

Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug Wegovy.

The Danish drugmaker first filed lawsuits over the sale of copycat versions of semaglutide last June, later amending one after samples it tested were found to be as much as 33% impure.

Read more at Reuters >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor